



## The 65th ASH Annual Meeting Abstracts

## POSTER ABSTRACTS

**617.ACUTE MYELOID LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS****Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged  $\geq 60$  Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)**

Adriano Venditti, MD<sup>1</sup>, Michal Kicinski<sup>2</sup>, Ernesta Audisio, MD<sup>3</sup>, Mario Luppi, MD<sup>4</sup>, Gianluca Gaidano, MD PhD<sup>5</sup>, Robin Foà, MD<sup>6</sup>, Anna Candoni<sup>7</sup>, Andrea Mengarelli, MD<sup>8</sup>, Attilio Olivieri<sup>9</sup>, Annalisa Imovilli, MD<sup>10</sup>, Maurizio Musso<sup>11</sup>, Paolo De Fabritiis, MD<sup>12</sup>, Eliana Zuffa, MD<sup>13</sup>, Nicola Cascavilla, MD<sup>14</sup>, Agostino Tafuri, MD<sup>15</sup>, Maria Ilaria Del Principe, MD<sup>16</sup>, Stefan Suci, PhD<sup>2</sup>, Anne Giraut, PhD<sup>17</sup>, Stéphanie Antunes<sup>18</sup>, Pierre W. Wijermans, MDPH<sup>19</sup>, Michael Lübbert, MD<sup>20</sup>, Geert A. Huls, Prof.<sup>21</sup>, Marco Vignetti, MD<sup>22</sup>, Francesco Buccisano, MD PhD<sup>23</sup>

<sup>1</sup> Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy

<sup>2</sup> EORTC Headquarters, Brussels, BEL

<sup>3</sup> SC EMATOLOGIA 2, AOU CITTA DELLA SALUTE E DELLA SCIENZA, OSPEDALE S. GIOVANNI BATTISTA MOLINETTE, Torino, ITA

<sup>4</sup> Hematology Unit and Chair, Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy

<sup>5</sup> Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Novara, ITA

<sup>6</sup> Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

<sup>7</sup> Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Udine, Italy

<sup>8</sup> Regina Elena National Cancer Institute, Rome, ITA

<sup>9</sup> Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy

<sup>10</sup> Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

<sup>11</sup> Division of Onco-Hematology and Stem Cell Transplantation, Clinica La Maddalena, Palermo, Italy

<sup>12</sup> Hematology Unit, Sant'Eugenio Hospital, Rome, Italy

<sup>13</sup> Hematology Unit, Ravenna, ITA

<sup>14</sup> Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Italy

<sup>15</sup> Azienda Ospedaliera Sant'Andrea, Rome, Italy

<sup>16</sup> Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Roma, Italy

<sup>17</sup> The European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium

<sup>18</sup> The European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussel, Belgium

<sup>19</sup> Department of Hematology, Haga Teaching Hospital, The Hague, The Netherlands; The Hague, Netherlands

<sup>20</sup> University Medical Center Freiburg, Freiburg, Germany

<sup>21</sup> Department of Hematology, University Medical Center Groningen, Groningen, Netherlands

<sup>22</sup> GIMEMA Foundation, Rome, Italy

<sup>23</sup> Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

**Introduction**

Several studies have demonstrated that patients with acute myeloid leukemia (AML) who test measurable residual disease (MRD) positive during or after treatment have a higher probability of relapse and a shorter duration of survival, as compared to those who are persistently MRD negative. Indeed, a status of MRD positivity reflects a condition of resistant disease, existing below the threshold of the morphologic evaluation of complete remission (CR). The bulk of our knowledge in terms of MRD assessment has been generated in the setting of intensive chemotherapy; much less is known for older patients receiving less intensive treatments, such as decitabine (DEC) using a 10-day schedule.

**Methods**

The AML21 study was a randomized open-label phase 3 clinical trial conducted by the EORTC Leukemia Group, GIMEMA, and GMDS-SG. Patients with a newly diagnosed AML, aged  $\geq 60$  years and eligible for intensive chemotherapy were randomized

1:1 to receive DEC (20mg/m<sup>2</sup> a day) using a 10-day schedule or intensive chemotherapy regimen consisting of daunorubicin 60 mg/m<sup>2</sup> x 3 days and cytarabine 200 mg/m<sup>2</sup> x 7 days (3+7), followed by 1-4 additional chemotherapy cycles. Patients who had an HLA-matched donor and at least stable disease were encouraged to undergo HSCT after >1 treatment cycle. Patients from the DEC arm not receiving HSCT could continue DEC treatment. A subset of patients treated in GIMEMA sites underwent a prospectively planned MRD evaluation post cycle 3 (DEC arm)/post consolidation (3+7 arm), and at 6, 12 and 18 months after the randomization, in case they were in a first CR and had not been allografted. MRD was studied by multiparameter flow cytometry. Based on several retrospective validations in the context of former EORTC/GIMEMA protocols, the threshold for discriminating MRD negative from MRD positive cases was set at 3.5x10<sup>-4</sup> (0.035%) residual leukemic cells, upon full blood count recovery.

### Results

In total, 130 out of 154 patients treated in GIMEMA centers provided consent for participation in translational research, had leukemia associated immunophenotype suitable for MRD monitoring, and initiated the protocol treatment, DEC (N=66) or 3+7 (N=64). Median age was 68 years (range 60-78), 33% of patients were ≥70 years old, 54% were male, and 31% and 30% had good and adverse European LeukemiaNet 2017 risk profile, respectively. At the MRD evaluation post cycle 3/consolidation, 9 out of 66 (14%) patients from the DEC and 12 out of 64 (19%) patients from the 3+7 arm had documented MRD negativity. The number of patients who either had documented MRD negativity or had undergone allografting and were alive and progression-free was 12 (18%) and 17 (27%) at 6 months, 14 (21%) and 13 (20%) at 12 months, and 14 (21%) and 7 (11%) at 18 months in the DEC and 3+7 arms, respectively. The inspection of individual profiles of patients who underwent the first MRD evaluation (and were at remission at that time) indicated that all MRD-positive patients from the DEC arm who were not allografted eventually relapsed, which often occurred just after the discontinuation of DEC maintenance.

### Conclusions

10-day DEC treatment can induce MRD-negativity. However, early MRD-negativity appeared more difficult to achieve with 10-day DEC than with 3+7. Among patients in whom 10-day DEC did not induce MRD-negativity, allografting or DEC maintenance appeared necessary to avoid a disease relapse.

**Disclosures Venditti:** Janssen: Consultancy, Honoraria, Other: travel support ; Amgen: Consultancy, Honoraria, Other: travel support ; Jazz: Consultancy, Honoraria, Other: travel support ; Medac: Consultancy; AbbVie: Consultancy, Honoraria, Other: travel support ; Pfizer: Consultancy, Honoraria, Other: travel support , Speakers Bureau; Novartis: Consultancy, Honoraria, Other: travel support . **Kicinski:** MSD: Research Funding; BMS: Research Funding; Pierre Fabre: Research Funding; JnJ: Research Funding; Immunocore: Research Funding. **Luppi:** Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Gilead Sci: Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant; Abbvie: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; Grifols: Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. **Gaidano:** Abbvie, Astra-Zeneca, BeiGene, Incyte, Janssen, Lilly: Other: Advisory board; Abbvie and Janssen: Speakers Bureau. **Candoni:** Janssen: Honoraria; Astellas: Honoraria; Pfizer: Consultancy; Incyte: Consultancy, Honoraria. **Lübbert:** Otsuka: Membership on an entity's Board of Directors or advisory committees; Imago Biosciences: Other: study drug; Syros: Membership on an entity's Board of Directors or advisory committees; Cheplapharm: Other: Study drug; Janssen-Cilag: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees; Astex Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees. **Vignetti:** IQVIA: Honoraria; AbbVie: Honoraria; Uvet: Honoraria; Dephaforum: Honoraria; ER Congressi: Honoraria; Novartis: Speakers Bureau. **Buccisano:** Novartis: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Becton Dickinson: Research Funding; BMS: Consultancy, Honoraria; Janssen & Cilag: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria; Astellas: Consultancy, Honoraria.

<https://doi.org/10.1182/blood-2023-184851>